Abstract

Cell mediated immunity plays a vital role in defense against influenza infection in humans. Less is known about the role of vaccine-induced cell mediated immunity and the cytokine responses elicited. We measured CD4+ and CD8+ T-cell reactivity in human subjects following vaccination with licensed trivalent influenza vaccine and a novel virus-like particle based vaccine. We detected influenza-specific CD4+ T-cell responses following vaccination with the licensed trivalent influenza vaccine and found that these correlated with antibody measurements. Administration of the novel virus-like particle based vaccine elicited influenza-specific CD4+ and CD8+ T-cell responses and the induction of the cytokines IFN-γ, IL-17A, IL17F, IL-5, IL-13, IL-9, IL-10 and IL-21. Pre-existing cytokine responses influenced the profile of the cytokine response elicited by vaccination. In a subset of individuals the VLP vaccine changed pre-vaccination production of type 2 cytokines such as IL-5 and IL-13 to a post-vaccination type 1 cytokine signature characterized by IFN-γ. A transcriptional signature to vaccination was found to correlate with antibody titer, IFN-γ production by T-cells and expression of a putative RNA helicase, DDX17, on the surface of immune cells.

Details

Title
Induction of Human T-cell and Cytokine Responses Following Vaccination with a Novel Influenza Vaccine
Author
Skibinski, David A G 1 ; Jones, Leigh Ann 2 ; Zhu, Yuan O 3 ; Lin Wu Xue 2 ; Au, Bijin 2   VIAFID ORCID Logo  ; Lee, Bernett 4 ; Mohamed Naim, Ahmad Nazri 3 ; Lee, Audrey 2 ; Kaliaperumal, Nivashini 2 ; Low, Jenny G H 5 ; Lee, Lawrence S 6 ; Poidinger, Michael 4 ; Saudan, Philippe 7 ; Bachmann, Martin 8 ; Ooi, Eng Eong 9 ; Hanson, Brendon J 10 ; Novotny-Diermayr, Veronica 11 ; Matter, Alex 11 ; Fairhurst, Anna-Marie 4   VIAFID ORCID Logo  ; Hibberd, Martin L 3 ; Connolly, John E 12 

 Institute of Molecular and Cell Biology, Singapore, Singapore; A*STAR Program in Translational Research on Infectious Disease, Agency for Science, Technology and Research, Singapore, Singapore 
 Institute of Molecular and Cell Biology, Singapore, Singapore 
 Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore, Singapore 
 Singapore Immunology Network (SIgN), 8A Biomedical Grove, Immunos Bldg, Singapore, Singapore 
 SingHealth Investigational Medicine Unit, Singapore General Hospital, Singapore, Singapore; Singapore General Hospital, Singapore, Singapore 
 Clinical Trials Research Unit, Changi General Hospital, Singapore, Singapore; National University of Singapore, Department of Medicine, Singapore, Singapore 
 Cytos Biotechnology AG, Zürich-Schlieren, Switzerland 
 Inselspital, RIA, Immunologie, Bern, Switzerland 
 Duke-NUS Medical School, Program in Emerging Infectious Diseases, Singapore, Singapore 
10  DSO National Laboratories, Bio-Defense Therapeutics Lab, Singapore, Singapore 
11  D3 (Drug Discovery and Development), Singapore, Singapore 
12  Institute of Molecular and Cell Biology, Singapore, Singapore; A*STAR Program in Translational Research on Infectious Disease, Agency for Science, Technology and Research, Singapore, Singapore; Institute of Biomedical Studies, Baylor University, Waco, Texas, USA 
Pages
1-12
Publication year
2018
Publication date
Dec 2018
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2159334554
Copyright
© 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.